Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • M&A / Deals
  • Arcera and Fosun sign MoU for neuroscience innovation
  • M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

Pharmaceutical Business Review

The initiative aligns with China's and the United Arab Emirates' (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Business Review

The initiative aligns with China’s and the United Arab Emirates’ (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

Post navigation

Previous: Rocket to sell PRV for $180m to advance gene therapy pipeline
Next: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

Related Stories

  • M&A / Deals

Solstice Oncology secures $225m to drive porustobart’s development for cancer

pharminent September 10, 2026
  • M&A / Deals

UK’s Claret Capital raises 575m for European biotechs

pharminent September 7, 2026
  • M&A / Deals

GSK wagers up to $1.3B on a different kind of cancer drug

pharminent September 3, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.